

2022 Share Purchase Plan Offer Results

Melbourne, Australia – 9 December 2022: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce the results of the Company’s Share Purchase Plan (SPP) Offer which closed on Monday, 5 December 2022.

The SPP Offer complemented the Company’s recently completed placement to new and existing institutional and sophisticated investors, raising \$13.5 million (Placement) (ASX announcement 16 September 2022) and provided existing shareholders with the opportunity to invest on the same terms.

The SPP Offer received total subscriptions of \$230,000, providing the Company with total funds to date of \$13.73 million when combined with the Placement.

As a result, 46 million new fully paid ordinary shares (New Shares) and 23 million New Options will be issued under the SPP Offer. The New Shares and New Options will be allotted on 12 December 2022, with holding statements despatched the following day, 13 December 2022.

Pursuant to the Prospectus dated 17 November 2022 under which the SPP and Shortfall Offers were made, 154 million New Shares and 77 million New Options remain available for subscription by Eligible Shareholders and Investors under the Shortfall Offer. The Shortfall Offer will close on a date to be determined by the Directors, but no later than 21 January 2023. The Prospectus and related Shortfall Offer Application Form can be accessed at <https://www.adherium.com/news/adherium-share-purchase-plan-spp-and-shortfall-offers-prospectus/>



The Adherium Board would like to thank its loyal shareholders who participated in the SPP for their ongoing support.

- ENDS -

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: Rick Legleiter
CEO
Adherium Limited
investors@adherium.com